Crossmark

Differentiating Cardiac Troponin Levels During Cardiac Myosin Inhibition or Cardiac Myosin Activation Treatments: Drug Effect or the Canary in the Coal Mine?

Crossref DOI link: https://doi.org/10.1007/s11897-023-00620-2

Published Online: 2023-10-25

Published Print: 2023-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Lee, Matthew M. Y.

Masri, Ahmad
License Information

Text and Data Mining valid from 2023-10-25

Version of Record valid from 2023-10-25
More Information

Article History

Accepted: 26 July 2023

First Online: 25 October 2023

Change Date: 1 December 2023

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1007/s11897-023-00639-5

Declarations

:

: Lee received research grants through his institution, the University of Glasgow, from AstraZeneca, Boehringer Ingelheim and Roche Diagnostics; is a member of a Trial Steering Committee for Cytokinetics and Clinical Endpoints Committee for Bayer.Masri received research grants from Ionis, Cytokinetics, and Pfizer; and fees (honoraria or consulting) from Cytokinetics, BMS, Eidos, Pfizer, Ionis, Alnylam, Attralus, Haya, BioMarin, Lexicon, and Tenaya.

: All reported studies with human or animal subjects performed by the authors have been previously published and complied with all applicable ethical standards (including the Helsinki declaration and its amendments, institutional/national research committee standards and international/national/institutional guidelines).

Updates are available Correction dated 2023-12-01

Click to view Correction: https://doi.org/10.1007/s11897-023-00639-5